HomeProductsBioactive CompoundsApoptosisBcl-2Gambogic Acid
Chemical structure of CAS 2752-65-0

Gambogic Acid

CAS No.2752-65-0
MDL No.MFCD16878985
MFC38H44O8
MW628.70
InChI KeyGEZHEQNLKAOMCA-RRZNCOCZSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.2752-65-0
Product NameGambogic Acid
Acute ToxicAcute Toxic
IrritantIrritant
Signal Word:Danger
HCode:H301-H315-H319-H335
PCode:P261-P264-P264+P265-P270-P271-P280-P301+P316-P302+P352-P304+P340-P305+P351+P338-P319-P321-P330-P332+P317-P337+P317-P362+P364-P403+P233-P405-P501

Related Articles

Studies related to this compound and its mechanism of action

Critical role of miR-26a-5p/Wnt5a signaling in gambogic acid-induced inhibition of gastric cancer.

Journal of biochemical and molecular toxicology • Vol. 35, Issue 4 • 2021
PMID: 33533530DOI: 10.1002/jbt.22721

Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.

Chemico-biological interactions • Vol. 235 • 2015
PMID: 25824409DOI: 10.1016/j.cbi.2015.03.017

Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation.

Toxicology in vitro : an international journal published in association with BIBRA • Vol. 28, Issue 3 • 2014
PMID: 24373880DOI: 10.1016/j.tiv.2013.12.008

The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.

Toxicology letters • Vol. 224, Issue 3 • 2014
PMID: 24291039DOI: 10.1016/j.toxlet.2013.11.021

Documentation

Similar Products